MMW - Fortschritte der Medizin

, Volume 160, Supplement 1, pp 35–42 | Cite as

Gefährliche Virusinfektion

Herpes zoster — was Sie als Hausarzt wissen müssen

FORTBILDUNG . ÜBERSICHT
  • 23 Downloads

Zusammenfassung

Die Gürtelrose manifestiert sich keinesfalls nur im Gürtelbereich. Schwere Verläufe mit Beteiligung der Augen, der Ohren, der Schleimhäute und sogar innerer Organe kommen vor. Zur Vermeidung der häufigsten Komplikation, der postzosterischen Neuralgie, sind eine rasche Diagnose und eine effiziente Therapie nötig. Hier sind Sie als Hausarzt gefragt.

Herpes zoster

Keywords

Varicella zoster virus herpes zoster postherpetic neuralgia patients at risk treatment 

Literatur

  1. 1.
    Jensen NJ, Rivailler P, Tseng HF, Quinlivan ML et al. Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. J Gen Virol. 2017;98:1434–8CrossRefGoogle Scholar
  2. 2.
    Weinberg A, Canniff J, Rouphael N, Mehta A et al. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12CrossRefGoogle Scholar
  3. 3.
    Kurapati S, Sadaoka T, Rajbhandari L, Jagdish B et al. Role of the JNK pathway in varicella-zoster virus lytic infection and reactivation. J Virol. 2017;91: pii: e00640–17CrossRefGoogle Scholar
  4. 4.
    Silva JR, Lopes AH, Talbot J, Cecilio NT et al. Neuroimmune-glia interactions in the sensory ganglia account for the development of acute herpetic neuralgia. J Neurosci. 2017;37:6408–22CrossRefGoogle Scholar
  5. 5.
    Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A et al. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis. 2017;17:356CrossRefGoogle Scholar
  6. 6.
    Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–30CrossRefGoogle Scholar
  7. 7.
    Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170CrossRefGoogle Scholar
  8. 8.
    Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70:178–86CrossRefGoogle Scholar
  9. 9.
    Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116:1643–51CrossRefGoogle Scholar
  10. 10.
    Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–15CrossRefGoogle Scholar
  11. 11.
    Winthrop KL, Yamanaka H, Valdez H, Mortensen E et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84CrossRefGoogle Scholar
  12. 12.
    Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28:846–52CrossRefGoogle Scholar
  13. 13.
    Schink T, Behr S, Thöne K, Bricout H, Garbe E. Risk of stroke after herpes zoster - evidence from a German self-controlled case-series study. PLoS One. 2016;11:e0166554CrossRefGoogle Scholar
  14. 14.
    Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017;17:198.CrossRefGoogle Scholar
  15. 15.
    Wollina U, Machetanz J. Herpes zoster and postzosterische Neuralgie. Hautarzt. 2016;67:653–65CrossRefGoogle Scholar
  16. 16.
    Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50:4120–2CrossRefGoogle Scholar
  17. 17.
    Wollina U. Variations in herpes zoster manifestation. Indian J Med Res. 2017;145:294–8PubMedPubMedCentralGoogle Scholar
  18. 18.
    Arruti M, Piñeiro LD, Salicio Y, Cilla G et al. Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014). J Neurovirol. 2017;23:451–9CrossRefGoogle Scholar
  19. 19.
    Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol. 2017;31:9–19CrossRefGoogle Scholar
  20. 20.
    Ultsch B, Siedler A, Rieck T, Reinhold T et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173CrossRefGoogle Scholar
  21. 21.
    Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster — guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017;31:20–9CrossRefGoogle Scholar
  22. 22.
    Wollina U. Herpes zoster. In: Katsambas A, Lotti T, Dessinioti C, D’Erme AM (Eds). European Handbook of Dermatological Treatments. 3rd Edition. Springer: Berlin Heidelberg 2015: pp. 379–84Google Scholar
  23. 23.
    Weaver BA, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (2011) Update on the advisory committee on immunization practices’ recommendations for use of herpes zoster vaccine. J Am Osteopath Assoc 2011;111(Suppl 6): S31–S33PubMedGoogle Scholar
  24. 24.
    Le P, Sabella C, Rothberg MB. Preventing herpes zoster through vaccination: New developments. Cleve Clin J Med. 2017;84:359–66CrossRefGoogle Scholar
  25. 25.
    Lal H, Cunningham AL, Godeaux O et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New Engl J Med. 2015;372:2087–96CrossRefGoogle Scholar
  26. 26.
    Cunningham AL, Lal H, Kovac M et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New Engl J Med. 2016;375:1019–32CrossRefGoogle Scholar
  27. 27.
    Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: A health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017;13:1495–1504CrossRefGoogle Scholar
  28. 28.
    Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35:3264–71CrossRefGoogle Scholar
  29. 29.
    Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies — update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441–50CrossRefGoogle Scholar
  30. 30.
    Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75:207–15CrossRefGoogle Scholar
  31. 31.
    Lin HC, Chao YH, Wu KH, Yen TY et al. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine (Baltimore). 2016;95:e4037CrossRefGoogle Scholar
  32. 32.
    Tsai SY, Chen HJ, Lio CF, Ho HP et al. Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. PLoS One. 2017;12: e0179447CrossRefGoogle Scholar
  33. 33.
    Ludvigsson JF, Choung RS, Marietta EV, Murray JA, Emilsson L. Increased risk of herpes zoster in patients with coeliac disease — nationwide cohort study. Scand J Public Health. 2017;1403494817714713. doi: 10.1177/1403494817714713. [Epub ahead of print]Google Scholar
  34. 34.
    Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7:e014032CrossRefGoogle Scholar
  35. 35.
    Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open Med. 2013;7:e68–73PubMedPubMedCentralGoogle Scholar
  36. 36.
    Schmidt SA, Mor A, Schønheyder HC, Sørensen HT et al. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis. J Infect. 2017;74:215–35CrossRefGoogle Scholar
  37. 37.
    Lai SW, Lin CH, Lin HF, Lin CL et al. Herpes zoster correlates with increased risk of Parkinson’s disease in older people: A population-based cohort study in Taiwan. Medicine (Baltimore). 2017;96:e6075CrossRefGoogle Scholar
  38. 38.
    Lin TY, Yang FC, Lin CL, Kao CH et al. Herpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort study. Medicine (Baltimore). 2016;95:e4480CrossRefGoogle Scholar
  39. 39.
    England BR, Mikuls TR, Xie F, Yang S et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheumatol. 2017; doi: 10.1002/art.40236. [Epub ahead of print]CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Städtisches Klinikum Dresden/FriedrichstadtKlinik für Dermatologie und AllergologieDresdenDeutschland

Personalised recommendations